Role of endothelin-1 in neovascularization of ovarian carcinoma

被引:192
作者
Salani, D
Di Castro, V
Nicotra, MR
Rosanò, L
Tecce, R
Venuti, A
Natali, PG
Bagnato, A
机构
[1] Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy
[2] Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy
[3] Regina Elena Inst Canc Res, Virol Lab, I-00158 Rome, Italy
[4] CNR, Inst Biotechnol, Rome, Italy
关键词
D O I
10.1016/S0002-9440(10)64791-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Endothelin-1 (ET-1) is overexpressed in ovarian carcinomas and acts, via ETA receptors (ETAR), as an autocrine growth factor. In this study we investigate the role of ET-1 in the neovascularization of ovarian carcinoma. Archival specimens of primary (n = 40) and metastatic (n = 8) ovarian tumors were examined by Immunohistochemistry for angiogenic factor and receptor expression and for microvessel density using antibodies against CD31, ET-1, vascular endothelial growth factor (VEGF), and their receptors. ET-1 expression correlated with neovascularization and with VEGF expression. The localization of functional ETAR and ETAR mRNA expression, as detected by autoradiography and irt situ hybridization, was evident in tumors and In intratumoral vessels, whereas ETBR were expressed mainly in endothelial cells. High levels of ET-1 were detected in the majority of ascitic fluids of patients with ovarian carcinoma and significantly correlated with VEGF ascitic concentration. Furthermore ET-1, through ETAR, stimulated VEGF production in an ovarian carcinoma cell Line, OVCA 433, by an extent comparable to hypoxia. Finally, conditioned media from OVCA 433 as well as ascitic fluids caused an Increase in endothelial cell migration and the ET-1 receptor blockade significantly inhibited this angiogenic response. These findings indicate that ET-1 could modulate tumor angiogenesis, acting directly and in part through VEGF.
引用
收藏
页码:1537 / 1547
页数:11
相关论文
共 45 条
[1]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[2]  
ALBERTS GF, 1994, J BIOL CHEM, V269, P10112
[3]  
Alvarez AA, 1999, CLIN CANCER RES, V5, P587
[4]  
Bagnato A, 1999, CANCER RES, V59, P720
[5]   Endothelins as autocrine regulators of tumor cell growth [J].
Bagnato, A ;
Catt, KJ .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (09) :378-383
[6]  
Bagnato A, 1995, CLIN CANCER RES, V1, P1059
[7]  
Bagnato A, 1997, CANCER RES, V57, P1306
[8]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516
[9]  
DAVOS K, 1999, ANN R COLL SURG ENGL, V81, P306
[10]   THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991